SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PepGen Inc. and its officers or directors [1] Group 1: Company Developments - On December 16, 2024, PepGen announced it received a clinical hold notice from the FDA regarding its IND application for the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular dystrophy [2] - Following the announcement of the clinical hold, PepGen's stock price decreased by $0.17 per share, or 3.63%, closing at $4.51 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]